Moving Forward: The Future of GLP-1 Therapies

The Endocrine Society recently held a virtual Science Writers Conference dedicated to the current landscape and future horizons of GLP-1 therapies, examining new oral formulations and dual and triple agonists. Endocrine News caught up with the two experts who spoke at the conference — Priya Jaisinghani, MD, DABOM and Mehmet Furkan Burak, MD – to learn what’s next for these medications and what they mean for people with obesity.

On December 10 last year, the Endocrine Society hosted a virtual Science Writers Conference focusing on what’s next for anti-obesity medications (AOMs), including the first pill formations of glucagon-like peptide-1 receptor agonists (GLP-1RAs). Indeed, the FDA approved the pill form of semaglutide (name brand Wegovy) just a couple of weeks later.

The webinar featured Priya Jaisinghani, MD, DABOM, clinical assistant professor at NYU Langone in New York, N.Y. – who discussed new and upcoming oral formulations of AOMs — and Mehmet Furkan Burak, MD, of Brigham and Women’s Hospital and Harvard Medical School in Boston, Mass.